The Conversation (0)
Celator Pharmaceuticals (NASDAQ:CPXX), developing cancer treatment therapies, announced today that the company has been approved for approximately $1.5 million in non-dilutive financing, through New Jersey’s Technology Business Tax Certificate Transfer Program.
Celator Pharmaceuticals (NASDAQ:CPXX), developing cancer treatment therapies, announced today that the company has been approved for approximately $1.5 million in non-dilutive financing, through New Jersey’s Technology Business Tax Certificate Transfer Program.
As quoted in the press release:
“We are thankful to have been approved for this program by the New Jersey Economic Development Authority (NJEDA) and for the ongoing support the biotechnology community receives from the State of New Jersey. We look for non-dilutive ways to fund our company, and plan to use this money to continue our research and development efforts in our oncology pipeline,” stated Fred M. Powell Vice President and Chief Financial Officer of Celator.
Read the full press release by Celator Pharmaceuticals (NASDAQ:CPXX)